Skip to main content

Advertisement

Table 3 Hemorrhagic and thrombotic complications

From: Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study

Complications TEG group (N = 21) aPTT group (N = 21) P value*
Patients with any bleeding, N (%) 10 (47.6) 15 (71.4) 0.21
Site of bleeding#, N (%)    
 CNS 0 (0) 0 (0)
 Gastrointestinal tract 3 (14.3) 1 (4.8) 0.61
 Vascular catheters insertion site 4 (19.0) 7 (33.3) 0.48
 ECMO cannula insertion site 5 (23.8) 5 (23.8) 1.0
 Mucosal bleeding (oral, nasal, airways) 6 (28.6) 10 (47.6) 0.34
 Surgical site (including tracheostomy) 0 (0) 6 (28.6) 0.02
 Urinary tract 2 (9.5) 5 (23.8) 0.41
Severity of bleeding (bleed type)    0.46
 Type 0, N (%) 11 (52.38) 9 (42.86)  
 Type 1, N (%) 1 (4.76) 3 (14.29)  
 Type 2, N (%) 8 (38.10) 5 (23.81)  
 Type 3, N (%) 1 (4.76) 3 (14.29)  
 Type 4, N (%) 0 (0.00) 1 (4.76)  
Patients with any thrombosis, N (%) 4 (19.0) 4 (19.0) 1.0
Site of thrombosis, N (%)    
Deep venous thrombosis (ECMO cannula-related) 2 (9.5) 3 (14.3) 1.0
Vascular catheter-related thrombosis 1 (4.8) 1 (4.8) 1.0
ECMO cannula occlusion 1 (4.8) 0 1.0
RBC transfused (ml/day/patient) 198 (37–330) 203 (155–247) 0.74
FFP transfused (ml/day/patient) 0 (0–79) 0 (0–0) 0.54
Platelet transfused (ml/day/patient) 0 (0–61) 0 (0–0) 0.28
  1. Data are reported as median (25th–75th percentile) or as absolute and relative frequencies as appropriate
  2. CNS central nervous system, ECMO extracorporeal membrane oxygenation, RBC red blood cells, FFP fresh frozen plasma
  3. #A patient could have more than one site of bleeding
  4. §Categories of bleeding according to Mehran et al. [18]
  5. *From Wilcoxon rank-sum (continuous variables) or Fisher’s exact (categorical variables) test